cDC1 is crucial in activating tumor-specific CD8+ T cells [23,24], whereas cDC2 promotes the activation of CD4+ T cells and has been known for driving anti-tumoral activities [29,30]. The gene discussed is MPPE1; the disease is neoplasm.